Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 1 |
2024 | 1 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean
fuqing tang
(1 results)?
Design, synthesis and biological evaluation of novel N-(methyl-d3) pyridazine-3-carboxamide derivatives as TYK2 inhibitors.
Bioorg Med Chem Lett. 2023 Apr 15;86:129235. doi: 10.1016/j.bmcl.2023.129235. Epub 2023 Mar 10.
Bioorg Med Chem Lett. 2023.
PMID: 36907336
Novel TYK2 Inhibitors with an N-(Methyl-d 3)pyridazine-3-carboxamide Skeleton for the Treatment of Autoimmune Diseases.
Liu F, Wang B, Liu Y, Shi W, Tang X, Wang X, Hu Z, Zhang Y, Guo Y, Chang X, He X, Xu H, He Y.
Liu F, et al.
ACS Med Chem Lett. 2022 Oct 6;13(11):1730-1738. doi: 10.1021/acsmedchemlett.2c00334. eCollection 2022 Nov 10.
ACS Med Chem Lett. 2022.
PMID: 36385928
Free PMC article.
Item in Clipboard
Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial.
Liang Y, Liu J, Ge J, Shi Q, Zhang G, Wan A, Luo T, Tian H, Fan L, Wang S, Chen L, Tang P, Zhu K, Jiang J, Bian X, Zhang Y, Qi X.
Liang Y, et al.
EClinicalMedicine. 2024 Apr 11;71:102585. doi: 10.1016/j.eclinm.2024.102585. eCollection 2024 May.
EClinicalMedicine. 2024.
PMID: 38638401
Free PMC article.
Item in Clipboard
Cite
Cite